lactic acid has been researched along with Multiple Myeloma in 20 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The small molecule 3-bromopyruvate (3-BP), which has emerged recently as the first member of a new class of potent anticancer agents, was tested for its capacity to kill multiple myeloma (MM) cancer cells." | 7.80 | Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy. ( Augustyniak, D; Bartkowiak, A; Goffeau, A; Gonchar, M; Ko, YH; Lis, P; Majkowska-Skrobek, G; Pedersen, PL; Ułaszewski, S, 2014) |
| "Type B lactic acidosis is rare among patients with malignant diseases." | 7.71 | Multiple myeloma associated with lactic acidosis. ( Burgess, R; Dainer, P; Fall, P; Hendricks, L; Jillella, A; Szerlip, HM; Ustun, C, 2002) |
| " In a recent issue of this journal, Van der Vreken, Oudaert I and colleagues showed that syrosingopine, together with another drug metformin, had a synergistic effect in killing cultured multiple myeloma (MM) cell lines, primary MM blasts from patients, and in a mouse MM model." | 4.31 | An acid test for metformin ( Benjamin, D, 2023) |
| " c-MYC also regulates glutamine metabolism and drives progression of asymptomatic precursor plasma cell (PC) malignancies to symptomatic multiple myeloma (MM)." | 3.88 | Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies. ( Dutta, T; Ghosh, T; Gonsalves, WI; Hitosugi, T; Jevremovic, D; Kumar, SK; Nair, KS; Petterson, XM; Ramakrishnan, V; Sakrikar, D; Wellik, L, 2018) |
| "The small molecule 3-bromopyruvate (3-BP), which has emerged recently as the first member of a new class of potent anticancer agents, was tested for its capacity to kill multiple myeloma (MM) cancer cells." | 3.80 | Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy. ( Augustyniak, D; Bartkowiak, A; Goffeau, A; Gonchar, M; Ko, YH; Lis, P; Majkowska-Skrobek, G; Pedersen, PL; Ułaszewski, S, 2014) |
| "Type B lactic acidosis is rare among patients with malignant diseases." | 3.71 | Multiple myeloma associated with lactic acidosis. ( Burgess, R; Dainer, P; Fall, P; Hendricks, L; Jillella, A; Szerlip, HM; Ustun, C, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 6 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 1 |
| Wang, L | 1 |
| Zhang, N | 1 |
| Xu, Y | 1 |
| Wang, CS | 1 |
| Zhang, XB | 1 |
| Zhu, XT | 1 |
| Chen, RS | 1 |
| Barbato, A | 1 |
| Giallongo, C | 1 |
| Giallongo, S | 1 |
| Romano, A | 1 |
| Scandura, G | 1 |
| Concetta, S | 1 |
| Zuppelli, T | 1 |
| Lolicato, M | 1 |
| Lazzarino, G | 1 |
| Parrinello, N | 1 |
| Del Fabro, V | 1 |
| Fontana, P | 1 |
| Aguennoz, M | 1 |
| Li Volti, G | 1 |
| Palumbo, GA | 1 |
| Di Raimondo, F | 1 |
| Tibullo, D | 1 |
| Van der Vreken, A | 1 |
| Oudaert, I | 1 |
| Ates, G | 1 |
| Faict, S | 1 |
| Vlummens, P | 1 |
| Satilmis, H | 1 |
| Fan, R | 1 |
| Maes, A | 1 |
| Massie, A | 1 |
| De Veirman, K | 1 |
| De Bruyne, E | 1 |
| Vanderkerken, K | 1 |
| Menu, E | 1 |
| Benjamin, D | 1 |
| Ma, NY | 1 |
| Li, Q | 1 |
| Li, XL | 1 |
| Zeng, YJ | 1 |
| Huang, DZ | 1 |
| Duan, YS | 1 |
| Xia, J | 1 |
| Liu, BD | 1 |
| Rao, LY | 1 |
| Rao, J | 1 |
| Zhang, X | 2 |
| Qin, X | 1 |
| Lin, L | 1 |
| Cao, L | 1 |
| Song, X | 1 |
| Hao, J | 1 |
| Zhang, Y | 2 |
| Wei, R | 1 |
| Huang, X | 1 |
| Lu, J | 1 |
| Ge, Q | 1 |
| Gonsalves, WI | 1 |
| Ramakrishnan, V | 1 |
| Hitosugi, T | 1 |
| Ghosh, T | 1 |
| Jevremovic, D | 1 |
| Dutta, T | 1 |
| Sakrikar, D | 1 |
| Petterson, XM | 1 |
| Wellik, L | 1 |
| Kumar, SK | 1 |
| Nair, KS | 1 |
| Walters, DK | 1 |
| Arendt, BK | 1 |
| Jelinek, DF | 1 |
| Majkowska-Skrobek, G | 1 |
| Augustyniak, D | 1 |
| Lis, P | 1 |
| Bartkowiak, A | 1 |
| Gonchar, M | 1 |
| Ko, YH | 1 |
| Pedersen, PL | 1 |
| Goffeau, A | 1 |
| Ułaszewski, S | 1 |
| Swami, A | 1 |
| Reagan, MR | 1 |
| Basto, P | 1 |
| Mishima, Y | 1 |
| Kamaly, N | 1 |
| Glavey, S | 1 |
| Zhang, S | 1 |
| Moschetta, M | 1 |
| Seevaratnam, D | 1 |
| Liu, J | 1 |
| Memarzadeh, M | 1 |
| Wu, J | 1 |
| Manier, S | 1 |
| Shi, J | 1 |
| Bertrand, N | 1 |
| Lu, ZN | 1 |
| Nagano, K | 1 |
| Baron, R | 1 |
| Sacco, A | 1 |
| Roccaro, AM | 1 |
| Farokhzad, OC | 1 |
| Ghobrial, IM | 1 |
| Bigley, AB | 1 |
| Rezvani, K | 1 |
| Pistillo, M | 1 |
| Reed, J | 1 |
| Agha, N | 1 |
| Kunz, H | 1 |
| O'Connor, DP | 1 |
| Sekine, T | 1 |
| Bollard, CM | 1 |
| Simpson, RJ | 1 |
| Li, L | 1 |
| Li, J | 1 |
| Cosco, D | 1 |
| Cilurzo, F | 1 |
| Maiuolo, J | 1 |
| Federico, C | 1 |
| Di Martino, MT | 1 |
| Cristiano, MC | 1 |
| Tassone, P | 1 |
| Fresta, M | 1 |
| Paolino, D | 1 |
| Vallejos, JR | 1 |
| Brorson, KA | 1 |
| Moreira, AR | 1 |
| Rao, G | 1 |
| Fujiwara, S | 1 |
| Kawano, Y | 1 |
| Yuki, H | 1 |
| Okuno, Y | 1 |
| Nosaka, K | 1 |
| Mitsuya, H | 1 |
| Hata, H | 1 |
| Ustun, C | 1 |
| Fall, P | 1 |
| Szerlip, HM | 1 |
| Jillella, A | 1 |
| Hendricks, L | 1 |
| Burgess, R | 1 |
| Dainer, P | 1 |
| Gramer, MJ | 1 |
| Ogorzalek, T | 1 |
| deZengotita, VM | 1 |
| Miller, WM | 1 |
| Aunins, JG | 1 |
| Zhou, W | 1 |
| Schlaeger, EJ | 1 |
| Schumpp, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Long-term Observational Study in Patients With Monoclonal Gammopathy of Undetermined Significance[NCT05539079] | 2,000 participants (Anticipated) | Observational | 2023-09-06 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 other studies available for lactic acid and Multiple Myeloma
| Article | Year |
|---|---|
CircKCNQ5 controls proliferation, migration, invasion, apoptosis, and glycolysis of multiple myeloma cells by modulating miR-335-5p/BRD4 axis.
Topics: Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Glycolysis; Humans; Lactic Aci | 2023 |
NBR2/miR-561-5p/DLC1 axis inhibited the development of multiple myeloma by activating the AMPK/mTOR pathway to repress glycolysis.
Topics: AMP-Activated Protein Kinases; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neo | 2022 |
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma.
Topics: Cell Line, Tumor; Humans; Lactic Acid; Multiple Myeloma; Proteasome Inhibitors; Symporters; Tumor Mi | 2023 |
Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Humans; Lactic Acid; Metformin; Monocarboxylic Acid Transpo | 2023 |
An acid test for metformin
Topics: Animals; Carrier Proteins; Cell Line, Tumor; Glycolysis; Hypoglycemic Agents; Lactic Acid; Metformin | 2023 |
Lactate Decreases Bortezomib Sensitivity and Predicts Poor Clinical Outcomes of Multiple Myeloma.
Topics: Apoptosis; Bortezomib; Drug Resistance, Neoplasm; Humans; Lactic Acid; Multiple Myeloma | 2023 |
Extracellular matrix protein Reelin promotes myeloma progression by facilitating tumor cell proliferation and glycolysis.
Topics: Animals; Cell Adhesion Molecules, Neuronal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Ext | 2017 |
Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Citric Acid Cycle; Disease Progression; DNA-Binding Proteins; G | 2018 |
CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells.
Topics: Basigin; Cell Proliferation; Down-Regulation; Gene Expression Profiling; Humans; Lactic Acid; Monoca | 2013 |
Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; Buthionine Sulfoximine; Cell Survival; Gl | 2014 |
Engineered nanomedicine for myeloma and bone microenvironment targeting.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Line, T | 2014 |
Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Part II: impact of latent cytomegalovirus infection and catecholamine sensitivity.
Topics: Adult; Cell Differentiation; Cell Line, Tumor; Cyclic AMP; Cytomegalovirus Infections; Cytotoxicity, | 2015 |
[Lentivirus-mediated shRNA silencing of LAMP2A inhibits the proliferation of multiple myeloma cells].
Topics: Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Lactic Acid; Lentivirus; Lysosomal-As | 2015 |
Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Chitosan; Drug Carriers; Humans; Lactic Acid; Mice; Mice, Inbred NOD | 2015 |
Dissolved oxygen and pH profile evolution after cryovial thaw and repeated cell passaging in a T-75 flask.
Topics: Animals; Biotechnology; Cell Culture Techniques; Cell Line, Tumor; Freezing; Glucose; Hydrogen-Ion C | 2010 |
PDK1 inhibition is a novel therapeutic target in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Dichloroacetic Acid; Glucose; Glycolysis; Humans; Lacta | 2013 |
Multiple myeloma associated with lactic acidosis.
Topics: Acidosis, Lactic; Disease Progression; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Lactic | 2002 |
A semi-empirical mathematical model useful for describing the relationship between carbon dioxide, pH, lactate and base in a bicarbonate-buffered cell-culture process.
Topics: Algorithms; Animals; Bicarbonates; Bioreactors; Carbon Dioxide; Cell Culture Techniques; Cell Line, | 2007 |
Phosphate feeding improves high-cell-concentration NS0 myeloma culture performance for monoclonal antibody production.
Topics: Amino Acids; Antibodies, Monoclonal; Apoptosis; Biotechnology; Cell Culture Techniques; Humans; Lact | 2000 |
Propagation of a mouse myeloma cell line J558L producing human CD4 immunoglobulin G1.
Topics: Amino Acids; Ammonia; Animals; Antiviral Agents; CD4 Antigens; Cell Division; Cell Line; Chromatogra | 1992 |